FDA approves Vyzulta for open-angle glaucoma and ocular hypertension
The FDA has approved a New Drug Application for Vyzulta for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension....
List view / Grid view
The FDA has approved a New Drug Application for Vyzulta for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension....
A vaccine combining centralised ancestral genes from four major influenza strains appears to provide broad protection against influenza...
Patients with advanced breast cancer who are treated with a combination of drugs are at increased risk of suffering adverse side effects...
Infants with SMA are more likely to show gains in motor function and survive without assisted support when treated with nusinersen...
A topical gel made from a class of common blood pressure medications has been found to accelerate the healing process of chronic skin wounds...
Scientists have developed self-assembling polymer molecules - an advance that could improve the delivery of toxic drugs to tumours...
A new treatment for dermatomyositis reduced the severity of the disease in patients who were resistant to other therapies...
The FDA has granted accelerated approval to Calquence for the treatment of adults with mantle cell lymphoma...
The long-term use of proton pump inhibitors, a class of drugs commonly used to treat acid reflux, is linked to the risk of developing stomach cancer...
Researchers have published two systematic reviews revealing the safety of mefloquine for preventing malaria in travellers...
Study examines potential of scalpel-free surgery to manage tremor...
Dr Annalisa Jenkins was the first female doctor to serve on the front line during the conflict in the Gulf War. She talks to EPR as part of our Women in Pharma series, on how her experiences shaped her rationale as a leader, about her views on the importance of…
Researchers have designed synthetic beta cells that secrete insulin in response to high blood sugar...
The FDA has approved the 10 mg once-daily dose of Xarelto, for reducing the continued risk of recurrent venous thromboembolism...
Crisaborole and dupilumab approved for atopic dermatitis…